Perakizumab

From Food & Medicine Encyclopedia

Perakizumab
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number 89957-37-9
PubChem
DrugBank
ChemSpider none
KEGG


Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis.<ref>Statement On A Nonproprietary Name Adopted By The USAN Council - Perakizumab, American Medical Association.</ref> It binds to IL17A and acts as an immunomodulator.<ref>World Health Organization, 

 International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107, 
 WHO Drug Information, 
 2012,
 Vol. 26(Issue: 2),
 
 
 
 
 
 Full text,</ref>

This drug was developed by Genentech/Roche.

References[edit]

<references/>


Monoclonal antibodies for the immune system
Immune system
Human
Mouse
Chimeric
Humanized
* Immunosuppressive: Apolizumab§

Immune activation: Dostarlimab

Other: Ibalizumab
Chimeric + humanized
Interleukin
Inflammatory lesions


Interleukin receptor modulators
IL-1
IL-2
IL-3
IL-4
IL-5
* Agonists: Interleukin 5


Stub icon

This monoclonal antibody–related article is a stub. You can help WikiMD by expanding the page.

Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Perakizumab&oldid=6525708"